Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered
Public ClinicalTrials.gov record NCT02969343. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Brigham and Women's Hospital (BWH) Patient Safety Learning Laboratory (PSLL) focuses on developing health information technology (HIT) tools to engage patients, family, and professional care team members in reliable identification, assessment, and reduction of patient safety threats in real-time, before they manifest in actual harm.
Study identification
- NCT ID
- NCT02969343
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 21,000 participants
Conditions and interventions
Conditions
- Central Line-Associated Bloodstream Infection (CLABSI)
- Venous Thromboembolism
- Patient Fall
- Catheter-Associated Infection
- Severe Hypoglycemia
- Opioid-Related Severe Adverse Drug Event
- Hospital Acquired Pressure Ulcer
- Adverse Drug Event
- Severe Hospital Acquired Delerium
- Rapid Response Related to Arrhythmia
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2018
- Last update posted
- Jul 9, 2019
2015 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Central Line-Associated Bloodstream Infection (CLABSI) trials
Other public records listing Central Line-Associated Bloodstream Infection (CLABSI). Sorted by last update posted; newest first. Not a recommendation.
- NCT07746674: Central Line-Associated Bloodstream Infection QI Project Not yet recruiting
All Central Line-Associated Bloodstream Infection (CLABSI) trials →
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02969343, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2019 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02969343 live on ClinicalTrials.gov.